Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio
Pre-ANDA Litigation Strategy: The Complete Playbook for Building Unbreakable Drug Patent Portfolios For IP counsel, portfolio managers, R&D leads, and […]
The Post-Exclusivity Event Horizon: Strategic Forecasting of Generic and Biosimilar Entry
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
DrugPatentWatch in the news: The Biologic Patent Transparency Act.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
The Device Patent Wall: How Pharma Buys 4.7 Extra Years of Drug Exclusivity — and What It Costs Everyone
1. What This Article Covers and Why It Matters Now The baseline 20-year patent term for a small molecule drug
Drug Prices Are Breaking Healthcare Systems: The Complete Analyst’s Guide to Patent Strategy, Cost Containment, and the IRA’s Real Impact
Healthcare systems including hospitals are taking care-related and business-related steps to cope with rapidly increasing drug prices.
ANDA Litigation: The Complete Playbook for Pharmaceutical Patent Litigators, IP Teams, and Institutional Investors
1. The Hatch-Waxman Framework: Statute, Economics, and IP Valuation The Legislative Architecture The Drug Price Competition and Patent Term Restoration
Expired Drug Patents Are Worth More Than You Think: The Complete Playbook for IP Teams, Portfolio Managers, and Generic Entrants
Information contained in expired drug patents can be invaluable to researchers developing new products, but caution is required to avoid legal problems.
Flat Fee, Unlimited Drugs: The Payer License Agreement Playbook Reshaping Pharmaceutical Access
A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP
Day 181 Generic Drug Launch: The Definitive Analyst’s Guide to Identifying, Timing, and Winning Generic Entry Opportunities
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by
